Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for ...

In a report released on March 14, Akash Tewari from Jefferies maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a ...

Virginia's shift from upgrant grants for economic development projects to paying for performance has meant more ...

Jason joined Channel 9 Eyewitness News in 2006 ... A federal judge granted summary judgment in favor of Merck for part of the litigation involving the HPV vaccine, Gardasil.

The New Haven, Conn., biopharmaceutical company shared positive topline results from a Phase 2a trial of Haduvio for the treatment of patients with refractory chronic cough. Haduvio met the primary ...

Taking a new tack There's no word yet on the drug targets that will be explored in the Cerevance partnership, but Merck head of neuroscience discovery, Jason Uslaner, said that the collaboration ...

Q4 2024 Earnings Call Transcript March 3, 2025 Mersana Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.16. Operator: Good morning, and welcome to Mersana ...

Nimbus Synergies led the round, with participation from Merck Global Health Innovation ... than foundation models in other domains” said Jason Robertson, managing partner at Nimbus Synergies.

Jason will discuss our increased target for OpEx ... We knew these deals with Novo Nordisk and Merck and Pfizer and so on to support drug discovery or manufacturing, R&D. We are getting large ...

ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating that tecovirimat did not improve mpox resolution. The results from STOMP ...

Syngene International Limited ('Syngene'), a global contract research, development, and manufacturing organization (CRDMO), today announced the acquisition of its first biologics site in the USA ?